Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 302

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 302
---
 development activities and regulatory operations. We do not allocate stock-based compensation or facility expenses to specific programs because these costs are deployed across multiple programs.

The following is a summary of our research and development expenses (in thousands, except for percentages):

 Three Months EndedMarch 31,Increase (Decrease) from 2024 to 2025Program Expenses:20252024$%Shingles$6,987 $3,266 $3,721 114 %Tdap113 1,592 (1,479)(93)%Plague (1)1,240 1,322 (82)(6)%HEPLISAV-B and CpG 1018 adjuvant development1,948 1,291 657 51 %Other5,512 2,701 2,811 104 %Other research and development expenses:Facility costs593 691 (98)(14 %)Non-cash stock-based compensation2,984 2,665 319 12 %Total research and development$19,377 $13,528 $5,849 43 %

(1)In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine utilizing CpG 1018 adjuvant. Under the agreement, we conducted a Phase 2 clinical trial and studies combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. We are being fully reimbursed by the DoD for the costs of this study, which is recorded in other revenue in our condensed consolidated statements of operations. 

Research and development expenses increased by $5.8 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase was primarily driven by an increase of $3.7 million in Shingles program expenses related to the ongoing Phase 1/2 clinical trial, an increase of $2.8 million related to the expected initiation of our phase 1/2 clinical study on Pandemic flu, and an increase of $2.0 million related to our IND-enabling study on Lyme disease initiated in the first quarter of 2025, partially offset by a decrease of $1.5 million in connection with the discontinuation of the Tdap program announced in November 2024, and a $1.2 million decrease incurred on other preclinical stage assets.

As we continue to